Skip to main content Accessibility help
×
Home

New Anticoagulants for Atrial Fibrillation: The Beginning of a A New Era in Stroke Prevention

  • David J. Gladstone (a1), Karen M. Earl (a2), Tammy J. Bungard (a3), Jafna L. Cox (a4), Alan Bell (a5), Paul Dorian (a6), Naeem Dean (a7), Thao Huynh (a8), Anil Chopra (a9), John Eikelboom (a10) and Ashfaq Shuaib (a11)...
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      New Anticoagulants for Atrial Fibrillation: The Beginning of a A New Era in Stroke Prevention
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      New Anticoagulants for Atrial Fibrillation: The Beginning of a A New Era in Stroke Prevention
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      New Anticoagulants for Atrial Fibrillation: The Beginning of a A New Era in Stroke Prevention
      Available formats
      ×

Abstract

  • An abstract is not available for this content so a preview has been provided below. To view the full text please use the links above to select your preferred format.

Copyright

Corresponding author

Regional Stroke Prevention Clinic, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Room A442, Toronto, Ontario, M4N 3M5, Canada

References

Hide All
1.Public Health Agency of Canada. 2009 Tracking Heart Disease and Stroke in Canada [Internet]. [cited 2011Mar 21]. Available from: http://www.phac-aspc.gc.ca/publicat/2009/cvd-avc/indexeng.php
2.Gladstone, DJ, Blakely, J, Dorian, P, et al.Detecting paroxysmal atrial fibrillation after ischemic stroke and transient ischemic attack: if you don’t look, you won’t find. Stroke. 2008;39:e789.
3.Statistics Canada. Table 4 Population estimates by sex and age group as of July 1, 2010, Canada [Internet]. [cited 2011 Mar 21]. Available from: http://www.statcan.gc.ca/daily-quotidien/100929/dq100929b-eng.htm
4.Statistics Canada. Projected population by age group according to three projection secenarios at July 1, 2036 [Internet]. [cited 2011 Mar 21]. Available from: http://www40.statcan.gc.ca/l01/cst01/demo08d-eng.htm
5.Santini, M, Ricci, RP.The worldwide social burden of atrial fibrillation: what should be done and where do we go? J Interv Card Electrophysiol. 2006 Dec;17(3):1838.
6.Hart, RG, Pearce, LA, Agullar, MI.Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:85767.
7.Zimetbaum, PJ, Thosani, A, Yu, HT, et al.Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med. 2010;123:44653.
8.van Walraven, C, Jennings, A, Oake, N, Fergusson, D, Forster, AJ.Effect of study setting on anticoagulation control. A systematic review and metaregression. Chest. 2006;129:115566.
9.Matchar, DB, Samsa, GP, Cohen, SJ, Oddone, EZ, Jurgelski, AE.Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 2002;113(1): 4251.
10.Gladstone, DJ, Bui, E, Fang, J, et al.Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40:23540.
11.O’Donnell, M, Oczkowski, W, Fang, J, et al.Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol. 2006;5(9):74954.
12.Connolly, SJ, Pogue, J, Eikelboom, J, et al.Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:202937.
13.Bungard, TJ, Gardner, L, Archer, S, et al.Evaluation of a pharmacist-managed anticoagulation clinic - improving patient care. Open Medicine. 2009;3(1):1621.
14.Bungard, TJ, Ackman, ML, Ho, G, Tsuyuki, RT.Adequacy of anticoagulation in patients with atrial fibrillation coming to a hospital. Pharmacotherapy. 2000;20(9):10605.
15.Mariano, Z, Triveri, M, Atzema, C, Dorian, P.Utilization of anticoagulant therapy in the emergency department for patients with atrial fibrillation at high risk of stroke [abstract]. Can J Cardiol. 2009;25 Suppl B:S301.
16.Glader, EL, Sjolander, M, Eriksson, M, Lundberg, M.Persistent use of secondary prevention drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41:397401.
17.Gallagher, AM, Rietbrock, S, Plumb, J, Van Staa, TP.Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in clinical practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost. 2008;6:15006.
18.Budnitz, DS, Pollock, DA, Weidenbach, KN, Mendelsohn, AB, Schroeder, TJ, Annest, JL.National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):185866.
19.Bungard, TJ, Ghali, WA, McAlister, , et al.Physicians’ perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ. 2001;165(3):3012.
20.Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al.Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:113951.
20a.Eikelboom, JW, Wallentin, L, Connolly, SJ, et al.Risk of bleeding with 2 doses of Dabigatran compared with Warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RELY) trial. Circulation 2011;123(21):236372.
21.Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al.Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):18756.
22.Mahaffey, KW, Fox, KAA, ROCKETAF Investigators. Rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Presented, AHA Nov. 15, 2010. Available from: http://www.dtmi.duke.edu/website-administration/files/ROCKET-AF-LBCT-FINAL.ppt/view
23.Connolly, SJ, Eikelboom, J, Joyner, C, et al.Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):80617.
24.Camm, AJ, Kirchhof, P, Lip, GYH, et al.Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369429.
25.Cairns, JA, Connolly, SJ, McMurtry, S, Stephenson, M, Talajic, M, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27(1):7490.
26.Lindsay, MP, Gubitz, G, Bayley, M, Hill, MD, Davies-Schinkel, C, Singh, S, Phillips, S.Canadian best practice recommendations for stroke care (update 2010). On behalf of the Canadian Stroke Strategy Best Practices and Standards Writing Group. 2010; Ottawa, Ontario Canada: Canadian Stroke Network. [cited 2011 Mar 21]. Available from: http://www.strokebestpractices.ca
27.U.S. Food and Drug Administration. FDA Drug Safety Communication: Special storage and handling requirements must be followed for Pradaxa (dabigatran etexilate mesylate) capsules [Internet]. [cited 2011 Apr 6]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm248746.htm
28.Bungard, TJ, Bucci, C, Kertland, H, Pickering, J, Semchuk, WM.Preventing stroke in atrial fibrillation patients: a systematic approach. Can Pharm J. [In Press 2011].

New Anticoagulants for Atrial Fibrillation: The Beginning of a A New Era in Stroke Prevention

  • David J. Gladstone (a1), Karen M. Earl (a2), Tammy J. Bungard (a3), Jafna L. Cox (a4), Alan Bell (a5), Paul Dorian (a6), Naeem Dean (a7), Thao Huynh (a8), Anil Chopra (a9), John Eikelboom (a10) and Ashfaq Shuaib (a11)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed